stockrow
Friday 6 November 2026
Export LTRN’s income statement to Excel — free account
Lantern Pharma Inc.
LTRN Healthcare Biotechnology
- EPS
- −42.5%
- Free cash flow
- +25.3%
Quarter to June 2026, against a year earlier
0.57
0.04
+7.55%
Follow LTRN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(104.58%) | (123.51%) | (157.37%) | (400.91%) | |
| (86.16%) | (93.53%) | (112.37%) | (143.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(200.07%) | (270.30%) | (481.02%) | (448.31%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.56) | (1.44) | (1.34) | (1.13) | |
Free Cash Flow |
(16.86) | (15.68) | (15.07) | (14.08) | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(76.82%) | (94.15%) | (154.31%) | (339.71%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.89 | 0.92 | 0.95 | 0.75 | |
Depreciation/Fixed assets |
(5.89) | (5.61) | (6.42) | (7.43) | |
Capex/Depreciation |
0.02 | 0.01 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.56) | (1.44) | (1.34) | (1.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates